Serum free light chains and multiple myeloma: Is it time to extend their application?

In nonsecretory, oligo‐secretory, and light chain multiple myeloma patients, serial sFLC evaluation could precede biochemical and clinical disease progression, even in extramedullary relapse, thus initiating early treatment with novel anti‐MM agents.

Detalles Bibliográficos
Autores principales: Markovic, Uros, Leotta, Valerio, Tibullo, Daniele, Giubbolini, Rachele, Romano, Alessandra, Del Fabro, Vittorio, Parrinello, Nunziatina Laura, Cannizzaro, Maria Teresa, Di Raimondo, Francesco, Conticello, Concetta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7141730/
https://www.ncbi.nlm.nih.gov/pubmed/32274022
http://dx.doi.org/10.1002/ccr3.2636
Descripción
Sumario:In nonsecretory, oligo‐secretory, and light chain multiple myeloma patients, serial sFLC evaluation could precede biochemical and clinical disease progression, even in extramedullary relapse, thus initiating early treatment with novel anti‐MM agents.

Ejemplares similares